Dashyant Dhanak

10.4k total citations · 1 hit paper
59 papers, 3.2k citations indexed

About

Dashyant Dhanak is a scholar working on Molecular Biology, Organic Chemistry and Surgery. According to data from OpenAlex, Dashyant Dhanak has authored 59 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 19 papers in Organic Chemistry and 7 papers in Surgery. Recurrent topics in Dashyant Dhanak's work include Epigenetics and DNA Methylation (8 papers), Cardiovascular, Neuropeptides, and Oxidative Stress Research (7 papers) and Microtubule and mitosis dynamics (6 papers). Dashyant Dhanak is often cited by papers focused on Epigenetics and DNA Methylation (8 papers), Cardiovascular, Neuropeptides, and Oxidative Stress Research (7 papers) and Microtubule and mitosis dynamics (6 papers). Dashyant Dhanak collaborates with scholars based in United States, United Kingdom and Canada. Dashyant Dhanak's co-authors include Kristian Helin, Charalambos Andreadis, Fangping Zhao, Daniel E. Bauer, Anthony N. Shaw, Sunil R. Hingorani, David A. Tuveson, Craig B. Thompson, Georgia Hatzivassiliou and Stephen A. Douglas and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Dashyant Dhanak

56 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ATP citrate lyase inhibition can suppress tumor cell growth

2005 820 citations Dashyant Dhanak et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dashyant Dhanak United States	27	2.0k	766	426	409	396	59	3.2k
Joan M. Carboni United States	34	2.4k 1.2×	804 1.0×	1.4k 3.2×	217 0.5×	386 1.0×	75	4.0k
Joerg Kallen Switzerland	31	1.9k 0.9×	323 0.4×	738 1.7×	559 1.4×	329 0.8×	58	3.6k
Eddy Pasquier France	32	1.9k 0.9×	858 1.1×	1.4k 3.3×	191 0.5×	391 1.0×	69	4.0k
Mark J. Suto United States	30	1.5k 0.8×	320 0.4×	531 1.2×	117 0.3×	564 1.4×	88	2.6k
Angelika M. Burger United States	37	2.7k 1.4×	684 0.9×	981 2.3×	161 0.4×	491 1.2×	81	4.1k
Timothy Madden United States	37	2.1k 1.1×	714 0.9×	1.6k 3.8×	280 0.7×	164 0.4×	108	4.8k
Richard Kendall United States	24	1.8k 0.9×	476 0.6×	837 2.0×	173 0.4×	315 0.8×	43	3.0k
Sylvia A. Holden United States	31	2.8k 1.4×	1.6k 2.1×	1.4k 3.3×	221 0.5×	232 0.6×	85	4.4k
Yutaka Saitoh Japan	27	1.5k 0.7×	151 0.2×	262 0.6×	275 0.7×	726 1.8×	91	2.9k
Hailing Cheng China	25	3.2k 1.6×	664 0.9×	1.2k 2.8×	161 0.4×	273 0.7×	41	4.3k

Countries citing papers authored by Dashyant Dhanak

Since Specialization

Citations

This map shows the geographic impact of Dashyant Dhanak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dashyant Dhanak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dashyant Dhanak more than expected).

Fields of papers citing papers by Dashyant Dhanak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dashyant Dhanak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dashyant Dhanak. The network helps show where Dashyant Dhanak may publish in the future.

Co-authorship network of co-authors of Dashyant Dhanak

This figure shows the co-authorship network connecting the top 25 collaborators of Dashyant Dhanak. A scholar is included among the top collaborators of Dashyant Dhanak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dashyant Dhanak. Dashyant Dhanak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Al-Ani, Gada, Jennifer Zwicker, Shamama Javed, et al.. (2024). 29 (PB017): A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agents. European Journal of Cancer. 211. 114557–114557.

Ott, Heidi M., Alan P. Graves, Melissa B. Pappalardi, et al.. (2014). A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics. 13(12). 3062–3073. 35 indexed citations

Dhanak, Dashyant & Paul Jackson. (2014). Development and classes of epigenetic drugs for cancer. Biochemical and Biophysical Research Communications. 455(1-2). 58–69. 57 indexed citations

Helin, Kristian & Dashyant Dhanak. (2013). Chromatin proteins and modifications as drug targets. Nature. 502(7472). 480–488. 320 indexed citations

Shaw, Antony N., Rosanna Tedesco, Ramesh Bambal, et al.. (2009). Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase. Bioorganic & Medicinal Chemistry Letters. 19(15). 4350–4353. 37 indexed citations

Tedesco, Rosanna, Deping Chai, Michael G. Darcy, et al.. (2009). Synthesis and biological activity of heteroaryl 3-(1,1-dioxo-2H-(1,2,4)-benzothiadizin-3-yl)-4-hydroxy-2(1H)-quinolinone derivatives as hepatitis C virus NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(15). 4354–4358. 19 indexed citations

Jin, Jian, Ming An, Anthony Sapienza, et al.. (2008). Urotensin-II receptor antagonists: Synthesis and SAR of N-cyclic azaalkyl benzamides. Bioorganic & Medicinal Chemistry Letters. 18(14). 3950–3954. 14 indexed citations

Burton, George, Thomas W. Ku, Thomas J. Carr, et al.. (2007). Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activity. Bioorganic & Medicinal Chemistry Letters. 17(7). 1930–1933. 34 indexed citations

Luo, Lusong, Cynthia A. Parrish, Neysa Nevins, et al.. (2007). ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nature Chemical Biology. 3(11). 722–726. 92 indexed citations

10.

Bousette, Nicolas, Fu Hu, Eliot H. Ohlstein, et al.. (2006). Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. Journal of Molecular and Cellular Cardiology. 41(2). 285–295. 53 indexed citations

11.

Bousette, Nicolas, et al.. (2006). Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides. 27(11). 2919–2926. 45 indexed citations

12.

Burton, George, Thomas W. Ku, Thomas J. Carr, et al.. (2005). Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. Bioorganic & Medicinal Chemistry Letters. 15(6). 1553–1556. 58 indexed citations

13.

Hassan, Ghada S., et al.. (2005). A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. Journal of Molecular and Cellular Cardiology. 39(5). 785–791. 44 indexed citations

14.

Gu, Baohua, Victor K. Johnston, Lester L. Gutshall, et al.. (2003). Arresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives. Journal of Biological Chemistry. 278(19). 16602–16607. 55 indexed citations

15.

Behm, David J., Christopher L. Herold, Eliot H. Ohlstein, et al.. (2002). Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist. British Journal of Pharmacology. 137(4). 449–458. 42 indexed citations

16.

Dhanak, Dashyant, Michael G. Darcy, Richard M. Keenan, et al.. (2001). Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. Bioorganic & Medicinal Chemistry Letters. 11(11). 1445–1450. 23 indexed citations

17.

Dhanak, Dashyant, Michael G. Darcy, Anthony J. Jurewicz, et al.. (2001). Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1. Bioorganic & Medicinal Chemistry Letters. 11(11). 1441–1444. 16 indexed citations

18.

Dhanak, Dashyant, George Burton, Michael G. Darcy, et al.. (2000). Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease. Bioorganic & Medicinal Chemistry Letters. 10(20). 2279–2282. 10 indexed citations

19.

Dhanak, Dashyant, Richard M. Keenan, George Burton, et al.. (1998). Benzothiopyran-4-one based reversible inhibitors of the human cytomegalovirus (HCMV) protease. Bioorganic & Medicinal Chemistry Letters. 8(24). 3677–3682. 42 indexed citations

20.

Coates, William J., et al.. (1993). Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogs of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. Journal of Medicinal Chemistry. 36(10). 1387–1392. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact